An Open Multicenter Study of Clinical Efficacy and Safety of Urolastic, an Injectable Implant for the Treatment of Stress Urinary Incontinence: One-Year ObservationReport as inadecuate




An Open Multicenter Study of Clinical Efficacy and Safety of Urolastic, an Injectable Implant for the Treatment of Stress Urinary Incontinence: One-Year Observation - Download this document for free, or read online. Document in PDF available to download.

BioMed Research International - Volume 2015 2015, Article ID 851823, 5 pages -

Clinical Study

2nd Department of Gynecology, Medical University of Lublin, Ulica Jaczewskiego 8, 20-954 Lublin, Poland

Department of Gynecology and Gynecologic Oncology, Military Institute of Medicine, Ulica Szaserów 128, 04-141 Warsaw, Poland

Department of Gynecology and Gynecologic Oncology, Medical University of Białystok, Ulica M. Skłodowskiej-Curie 24a, 15-276 Białystok, Poland

Received 26 June 2014; Revised 18 September 2014; Accepted 21 September 2014

Academic Editor: Thomas Otto

Copyright © 2015 Konrad Futyma et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

The prevalence of stress urinary incontinence rises and affects up to 30% of women after 50 years of age. Midurethral slings are currently the mainstay of surgical anti-incontinence therapy. Some patients experience recurrent SUI RSUI which is defined as a failure of anti-incontinence surgery after a period of time or persistence of SUI after the procedure aimed at correcting it. The urethral bulking agent application decreases invasiveness of treatment and meets patients requirements. The objective of this study was to assess the safety and clinical efficacy of Urolastic injection. One hundred and five patients with SUI including 91 patients with RSUI were treated with Urolastic in three tertiary gynecological clinics. The efficacy of the procedure was assessed objectively at each follow-up visit by means of cough test and a standard 1-hour pad test. Objective success rate after 12 months after primary procedure in RSUI patients was found in 59.3% of patients. In 14 patients with primary SUI improvement after 1 year was found in 71.4% of patients. Although cure rates after MUS are up to 90% there is still place for less invasive treatment option like periurethral injection of bulking agents, especially in patients with previous SUI surgical management.





Author: Konrad Futyma, Paweł Miotła, Krzysztof Gałczyński, Włodzimierz Baranowski, Jacek Doniec, Agnieszka Wodzisławska, Macie

Source: https://www.hindawi.com/



DOWNLOAD PDF




Related documents